Choice may boost HIV prevention: a trial tests offering multiple PrEP options to young women in kenya

NCT ID NCT07076043

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This trial tests whether offering a menu of HIV prevention options — including daily pills and a vaginal ring — helps more young women aged 18–30 start and continue using PrEP. About 1,400 women seeking reproductive health services at clinics in Kenya will be offered either standard daily oral PrEP or a multi-product program that begins with the dapivirine ring. The study aims to see if having a choice leads to higher rates of PrEP initiation and persistence at three months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a multi-product PrEP program including daily oral PrEP and the dapivirine vaginal ring
What this could lead to
If it works, this could show that offering a choice of HIV prevention methods helps more young women protect themselves from HIV.
What could go wrong
The trial is testing a program, not a single drug, so results may depend on how well clinics implement the options. The dapivirine ring is one of several products and may not suit everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Kenya Medical Research Institute and Partners in Health & Research Development

    RECRUITING

    Thika, Kiambu County, Kenya

    Contact

    Contact

    Contact

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.